<DOC>
	<DOCNO>NCT02503540</DOCNO>
	<brief_summary>This interventional study evaluate retinal vascular dynamic associate Intravitreal Aflibercept Injection ( IAI ) therapy eye diabetic macular edema ( DME ) macular edema secondary retinal vein occlusion ( RVO ) . Ultra-widefield fluorescein angiography OCT angiography perform multiple timepoints assess change retinal vascular leakage , ischemia , vascular abnormality throughout study duration compare alteration baseline .</brief_summary>
	<brief_title>Peripheral Macular Retinal Vascular Perfusion Leakage DME RVO</brief_title>
	<detailed_description>Diabetic macular edema ( DME ) macular edema secondary retinal venous occlusive disease common cause vision loss retinal vascular disease . Recently VEGF inhibitor ( bevacizumab , aflibercept , ranibizumab ) describe new first-line therapy condition . Aflibercept recently approve VEGF inhibitor management condition . Clinical trial show treatment aflibercept improve visual acuity reduces macular edema large percentage patient . This study examine change occur intravitreal aflibercept perfusion leakage treatment naive eye course 1 year .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<criteria>Inclusion Criteria A subject must meet follow criterion eligible inclusion study : 1 . Signed Informed Consent . 2 . Men woman ≥ 18 year age . 3 . Fovealinvolving retinal edema secondary DME RVO base investigator review SDOCT . 4 . EETDRS bestcorrected visual acuity : 20/25 20/400 study eye Hand Motion ( HM ) study eye . 5 . Willing , commit , able return ALL clinic visit complete study related procedure . 6 . Able read , ( , unable read due visual impairment , read verbatim person administer informed consent family member ) understand willing sign inform consent form . Exclusion Criteria A subject meet follow criterion exclude study : 1 . Any prior concomitant therapy another investigational agent treat DME RVO study eye . 2 . Prior panretinal photocoagulation study eye . 3 . Prior intravitreal antiVEGF therapy study eye . 4 . Prior focal/grid laser photocoagulation study eye . 5 . Prior history intravitreal steroid therapy study eye . 6 . Any history allergy fluorescein sodium reason patient unable undergo fluorescein angiography ( e.g. , inability get vascular access , unable tolerate procedure ) 7 . Prior systemic antiVEGF therapy , investigational FDAapproved , allow 3 month prior first dose , allow study . 8 . Significant vitreous hemorrhage obscure view macula retinal periphery determine investigator clinical exam ultrawidefield angiography . 9 . Presence cause macular edema , include myopic degeneration , ocular histoplasmosis syndrome , angioid streak , choroidal rupture , choroidal neovascularization , neovascular agerelated macular degeneration multifocal choroiditis study eye . Epiretinal membrane allow . 10 . Presence maculathreatening traction retinal detachment . 11 . Prior vitrectomy study eye . 12 . History retinal detachment treatment surgery retinal detachment study eye . 13 . Any history macular hole stage 2 study eye . 14 . Any intraocular periocular surgery within 3 month Day 1 study eye , except lid surgery , may take place within 1 month day 1 , long 's unlikely interfere injection . 15 . Prior trabeculectomy filtration surgery study eye . 16 . Uncontrolled glaucoma baseline evaluation ( defined intraocular pressure ≥25 mmHg despite treatment antiglaucoma medication ) study eye . 17 . Active intraocular inflammation either eye . 18 . Active ocular periocular infection either eye . 19 . Any ocular periocular infection within last 2 week prior Screening either eye . 20 . Any history uveitis either eye . 21 . Active scleritis episcleritis either eye . 22 . Presence history scleromalacia either eye . 23 . Aphakia study eye . 24 . Previous therapeutic radiation region study eye . 25 . History fullthickness penetrate keratoplasty study eye . Partial thickness corneal transplant include DSAEK DMEK allow . 26 . Significant medium opacity , include cataract , study eye might interfere visual acuity , assessment safety , fundus photography . 27 . Any concurrent intraocular condition study eye ( e.g . cataract ) , opinion investigator , could require either medical surgical intervention 52 week study period . 28 . Any concurrent ocular condition study eye , opinion investigator , could either increase risk subject beyond expect standard procedure intraocular injection , otherwise may interfere injection procedure evaluation efficacy safety . 29 . Participation subject clinical study within 12 week prior Day 1 . 30 . Any systemic therapy investigational agent past 3 month prior Day 1 . 31 . Any history allergy povidone iodine . 32 . Pregnant breastfeed woman 33 . Women childbearing potential* unwilling practice adequate contraception study ( adequate contraceptive measure include stable use oral contraceptive prescription pharmaceutical contraceptive 2 menstrual cycle prior screen ; intrauterine device [ IUD ] ; bilateral tubal ligation ; vasectomy ; condom plus contraceptive sponge , foam , jelly , diaphragm plus contraceptive sponge , foam , jelly ) Postmenopausal woman must amenorrheic least 12 month order consider child bear potential . Pregnancy test contraception require woman document hysterectomy tubal ligation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>macular edema</keyword>
	<keyword>rvo</keyword>
	<keyword>diabetic macular edema</keyword>
</DOC>